| 英文摘要 |
This study aimed to evaluate the effects of ''AMS BioteQ Energy Drink”on the quality of life (QoL) in cancer patients undergoing chemotherapy or chemoradiotherapy. This single-center, prospective, single-arm interventional study enrolled 50 participants who consumed one bottle of the vitality drink twice daily for three months. QoL changes were assessed using the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline and at months 1, 3, 6, 9, and 12. Results showed that after one month of consumption (N = 47), the overall QoL score significantly increased from 75.0 at baseline to 79.5 (p = 0.003). By the third month (N = 44), the score further improved to 87.4 (p < 0.001), and reached 90.0 at the sixth month (N = 35; p < 0.001). Following discontinuation, the score decreased to 86.7 at month 9 (N = 36, p = 0.007) and 85.8 at month 12 (N = 31, p = 0.004), yet remained significantly higher than baseline (p < 0.001). Scores in all four QoL domains significantly improved after three months (p≤0.001). However, after discontinuation, social/family well-being and emotional well-being scores gradually declined, showing no significant difference from baseline at month 12. This study demonstrates that three months of vitality drink consumption significantly improves QoL in cancer patients. While some effects diminish after discontinuation, overall QoL remains higher than baseline, supporting the potential of the vitality drink as an adjunct health supplement. |